NPM1 and leukemia: Furthermore, FLT3-ITD leukemias with mutations in NPM1 or DNMT3A exhibit a different drug response mechanism to the FLT3 inhibitor quizartinib, where the cell differentiation effect predominates over the cytotoxic mechanism [22].